Skip Navigation


American Journal of Epidemiology Advance Access originally published online on August 23, 2006
American Journal of Epidemiology 2006 164(9):862-872; doi:10.1093/aje/kwj287
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
164/9/862    most recent
kwj287v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Costacou, T.
Right arrow Articles by Orchard, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Costacou, T.
Right arrow Articles by Orchard, T. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

American Journal of Epidemiology Copyright © 2006 by the Johns Hopkins Bloomberg School of Public Health All rights reserved; printed in U.S.A.

Original Contribution

Identifying Genetic Susceptibilities to Diabetes-related Complications among Individuals at Low Risk of Complications: An Application of Tree-Structured Survival Analysis

Tina Costacou1, Yuefang Chang2, Robert E. Ferrell3 and Trevor J. Orchard1

1 Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA
2 Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA
3 Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA

Correspondence to Dr. Trevor J. Orchard, University of Pittsburgh, Diabetes and Lipid Research Building, 3512 Fifth Avenue, Pittsburgh, PA 15213 (e-mail: tjo{at}pitt.edu).

Received for publication September 14, 2005. Accepted for publication April 10, 2006.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 References
 
The authors hypothesized that genetic predisposition to diabetes complications would be more evident among low-risk individuals and aimed to identify genes related to developing complications (confirmed distal symmetric polyneuropathy, overt nephropathy, or coronary artery disease) in low-risk groups. Participants in the Pittsburgh, Pennsylvania, Epidemiology of Diabetes Complications Study of childhood-onset type 1 diabetes, first seen in 1986–1988 (mean age, 28 years; diabetes duration, 19 years), were reexamined biennially for 10 years. For each complication, subgroups with the lowest disease risk were identified by using tree-structured survival analysis, and 15 candidate genes were compared between subjects with and without complications. In the group with the lowest incidence of confirmed distal symmetric polyneuropathy (n = 123), confirmed distal symmetric polyneuropathy risk increased fivefold for those with the eNOS GG genotype (p < 0.05). In the group with the lowest risk of overt nephropathy (n = 340), the ACE D polymorphism increased overt nephropathy risk twofold (p = 0.05), whereas a protective effect was observed for the LIPC CC genotype (p < 0.05). In the group with the lowest incidence of coronary artery disease (n = 331), the MTHFR CC genotype increased coronary artery disease risk threefold (p < 0.05). Tree-structured survival analysis may help identify genetic predispositions among individuals who, despite low risk, develop diabetes-related complications.

diabetes complications; diabetes mellitus; genetic predisposition to disease; statistics; survival analysis

Abbreviations: ACE, angiotensin-converting enzyme; eNOS, endothelial nitric oxide synthase; HDL, high density lipoprotein; LIPC, hepatic lipase; MTHFR, methylenetetrahydrofolate reductase; TSSA, tree-structured survival analysis


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 References
 
Despite strong associations between glycemic control and microvascular complications in type 1 diabetes (1Go–4Go), there is still considerable variability in the risk of complications, suggesting that certain patient subgroups are particularly prone or resistant. Recent studies have clearly shown familial clustering of complications, in particular renal disease, providing further support for a genetic predisposition (5Go–7Go). However, as reviewed by Rich et al. (8Go), no consensus has been reached, at least as far as human lymphocyte antigen–associated genetic susceptibilities are concerned. We propose that the genetic component may be particularly important in subgroups at either end of the risk spectrum, as determined by known risk factors, because most individuals will develop complications on the basis of standard risk factors (e.g., glycemia, blood pressure, lipids). We also propose that studies in these extreme subgroups may reveal genetic markers of susceptibility that extend beyond the sole influence of the main risk factors. If this hypothesis holds true, then it would be easier to identify individuals with a genetic susceptibility to diabetes-related complications among those with a better overall risk profile (or, alternatively, to identify protective genes in those with a high-risk profile). This general approach we have previously found helpful; for example, we were able to identify three genetic markers for the development of overt nephropathy, by comparing those at high and low risk, that were not evident in the study population as a whole (9Go).

Our objective was to identify those individuals with a genetic susceptibility to three diabetes-related complications, namely, confirmed distal symmetric polyneuropathy, overt nephropathy, and coronary artery disease, among patients at seemingly low risk. To do so, we used the 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study, a prospective cohort of childhood-onset type 1 diabetes. Survival data have traditionally been analyzed by using Cox proportional hazards modeling (10Go). Newer regression techniques, such as tree-structured analysis, also known as recursive partitioning, provide one potential approach to identifying subgroups of patients characterized by the presence or absence of specific risk factors and who differ in disease risk (11Go–13Go). Tree-based classification does not require the assumption that the ratios of the hazards for the groups being compared are constant. We used this classification approach with an extension to survival data (tree-structured survival analysis (TSSA)) to facilitate the search for genetic factors whose influence may be apparent in only those at high or low overall risk. These analyses, which focus on the effect of genetic factors, are primarily considered hypothesis generating and need to be replicated despite the plausibility of the candidate genes studied.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 References
 
The population selected for study was a historical, prospective cohort based on incident cases of childhood-onset (children <17 years of age) type 1 diabetes diagnosed or seen within 1 year of diagnosis at Children's Hospital of Pittsburgh, Pennsylvania, between 1950 and 1980 (14Go, 15Go). Although this population is clinic based, it has been shown to be representative of the type 1 diabetes population of Allegheny County, Pennsylvania (16Go). This cohort was first examined for the Pittsburgh Epidemiology of Diabetes Complications study between 1986 and 1988, when mean age was 28 years and diabetes duration was 19 years. Subjects were subsequently reexamined biennially for 10 years. Prior to each of the scheduled clinic visits, participants were sent questionnaires concerning demographic, health care, self-care, and medical history information. The University of Pittsburgh Institutional Review Board approved the study protocol.

Definition of complications and risk factors
Confirmed distal symmetric polyneuropathy was determined by a study-trained physician using the Diabetes Control and Complications Trial clinical examination protocol (17Go) and was diagnosed by the presence of at least two of the following states: symptoms and/or signs consistent with distal symmetric polyneuropathy and absent (or decreased) tendon reflexes, all in the absence of other known etiologies, in addition to the presence of a vibratory threshold above the age-specific normal range using the Vibratron II tester (Physitemp Instruments Inc., Clifton, New Jersey) and a forced-choice methodology (18Go, 19Go). Of 658 participants, 64 (9.7 percent) who did not return for a follow-up examination and 187 with prevalent confirmed distal symmetric polyneuropathy were excluded from analyses. Of the remaining 407, 370 had complete information on covariates examined and were thus included in analyses for the prediction of distal symmetric polyneuropathy incidence.

Overt nephropathy was defined as an albumin excretion rate of >200 µg/minute on at least two of three timed urine specimens, or, in the absence of urine, a serum creatinine level of >2 mg/dl, or renal failure or renal transplant. Follow-up overt nephropathy status could not be determined for 58 (8.8 percent) participants who did not return for a clinical examination. Another 171 were diagnosed with overt nephropathy at study entry and were thus excluded from analyses for the prediction of incident renal disease, along with 37 whose information on covariates examined was not complete.

Coronary artery disease was determined by study physician–diagnosed angina or myocardial infarction confirmed by Q waves on electrocardiogram or hospital records (Minnesota codes 1.1 or 1.2), or angiographic stenosis ≥50 percent, coronary artery bypass surgery, angioplasty, or ischemic electrocardiogram changes (Minnesota codes 1.3, 4.3, 4.2, 5.1, 5.3, 7.1) during the follow-up period of the study. Follow-up coronary artery disease status could not be determined for three participants (0.5 percent) who did not return for a follow-up examination. Fifty-two prevalent coronary artery disease cases as well as 64 persons lacking information on covariates examined were excluded from the analyses for the prediction of coronary artery disease incidence.

The proportion of participants excluded from analyses because of failure to return for a follow-up examination, and thus inability to ascertain disease status, varies by complication. This variation relates to the definition of each complication and the ability to determine disease status without a subject actually returning for a clinical examination. Thus, if a participant free of complications at baseline was unable to return for a follow-up visit but provided survey information indicating the presence of a specific condition (e.g., heart attack), that condition would be diagnosed, whereas the presence of other complications (e.g., overt nephropathy, which requires urine samples) could not be identified.

Blood pressure was measured with a random zero sphygmomanometer, according to the Hypertension Detection and Follow-up Program protocol, after a 5-minute rest (20Go). Hypertension was defined as blood pressure ≥140/90 mmHg or use of antihypertensive medication. Stable glycosylated hemoglobin was measured by ion exchange chromatography (Isolab, Akron, Ohio) and subsequently by automated high-performance liquid chromatography (Diamat, BioRad, Hercules, California). Readings obtained with the two methods are almost identical (r = 0.95). High density lipoprotein (HDL) cholesterol was determined by a precipitation technique (heparin and manganese chloride) with a modification (21Go) of the Lipid Research Clinics method (22Go). Cholesterol and triglycerides were measured enzymatically (23Go, 24Go). Low density lipoprotein cholesterol levels were calculated from measurements of the levels of total cholesterol, triglycerides, and HDL cholesterol by using the Friedewald equation (25Go). Smoking status (ever/never) was obtained via self-report.

Glucose disposal rate (insulin sensitivity) was estimated by using a regression equation (24.31 – (12.22 x waist-to-hip ratio) – (3.29 x hypertension) – (0.57 x glycosylated hemoglobin)) derived from hyperinsulinemic euglycemic clamp studies on 24 study subjects chosen to represent the full spectrum of insulin resistance as identified by insulin resistance risk factors (26Go). White blood cell count was obtained by using a counter S-plus IV (Coulter Electronics, Inc., Hialeah, Florida) and fibrinogen by using a biuret colorimetric procedure and a clotting method.

For the 1999–2004 Pittsburgh Epidemiology of Diabetes Complications Study grant period, 15 genetic polymorphisms were proposed for study. All had suspected potential roles in the pathogenesis of complications through linkage to blood pressure, lipoprotein metabolism, glucose metabolism, glycosylation, or inflammation. Of these 15 polymorphisms, associations were found for four with the three diabetes complications examined (genetic polymorphisms not presented in the paper are included in appendix table 1). High-molecular-weight genomic DNA was isolated from ethylenediaminetetraacetic acid anticoagulant whole blood by the method of Miller et al. (27Go). The angiotensin-converting enzyme (ACE) insertion/deletion polymorphism and the methylenetetrahydrofolate reductase (MTHFR), endothelial nitric oxide synthase (eNOS), and hepatic lipase (LIPC) genotypes were determined by the methods of Tiret et al. (28Go), Frosst et al. (29Go), Nakayama et al. (30Go), Hibi et al. (31Go), and Couture et al. (32Go). Genotypes were assigned by direct comparison with controls of known genotype.

Statistical analyses
The association of candidate genes with type 1 diabetes complications was evaluated by comparing the genotypes in the lowest risk groups generated by TSSA (12Go, 13Go). TSSA, a nonparametric statistical method, extends tree-based methods such as the classification and regression tree (11Go). The main objective of a tree-based method is to classify subjects into subgroups according to their characteristics and outcome so that, within each subgroup, the risk factors are similar but, between subgroups, the outcomes are distinct. Briefly, a tree model is built starting with the complete sample of subjects as one group, the root node. Subjects are then partitioned to two subgroups (or nodes) based on a predictor variable that separates the subgroups most in the outcome. The process is then repeated in each node, with a predictor being selected each time until no further dividing is worthwhile. TSSA extends the tree construction methodology to survival data taking into consideration time to event, so that within-group homogeneity in risk factors and between-group separation in survival experience are optimized.

TSSAs were conducted for the prediction of three diabetes-related complications: confirmed distal symmetric polyneuropathy, overt nephropathy, and coronary artery disease. Baseline risk factors used in the analyses for all three outcomes included diabetes duration, age at diabetes onset, serum creatinine, fibrinogen, having ever smoked, total cholesterol, triglycerides, systolic blood pressure, white blood cell count, and estimated glucose disposal rate, based on earlier analyses (9Go, 33Go, 34Go). Behavioral and socioeconomic risk factors were not considered. Subjects who were free from the complication at baseline and for whom all the risk factors were available were included in the TSSA (in total, 567 participants free of at least one complication at baseline were included in these analyses). Once the subgroups were identified from TSSA for each complication, the relation between the candidate gene and complication was examined in the lowest risk group. DNA was determined in 443 (78.1 percent) participants; however, two genotyping failures occurred for the eNOS, three for the ACE, 15 for the LIPC, and 28 for the MTHFR genotypes. Of the 15 genes considered, associations were found for four polymorphisms; results for the latter are reported here. Clearly, this candidate gene approach to studying three different complications inevitably leads to multiple comparisons. Whereas we present results on the basis of p < 0.05 on the grounds that this is a hypothesis-generating analysis only, a corrected Bonferroni level of significance would be <0.003 given 15 genes. None of the four polymorphisms reported reached this level of significance.

In the current study, the TSSA was conducted by using S-Plus programs written by Dr. Mark Segal (Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California). Descriptive statistical analyses (Student's t tests and chi-square tests for univariate associations between baseline risk factors and complication status during 10 years of follow-up) as well as estimates of risk were generated by using SAS version 8.2 software (SAS Institute, Inc., Cary, North Carolina). All reported p values are two sided. Because hazard ratios were calculated using groups of participants already characterized by their baseline risk attributes, adjustment was performed for diabetes duration only.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 References
 
Baseline characteristics of participants by the incidence of complications during 10 years of follow-up are shown in table 1, whereas duration-adjusted hazard ratios for each of the four polymorphisms are shown in table 2. With the exception of protection against renal disease incidence among those with the LIPC CC genotype, no significant genetic associations were observed in the overall cohort by diabetes complication.


View this table:
[in this window]
[in a new window]

  		TABLE 1. Baseline characteristics{dagger} of participants by incidence of complications during 10 years of follow-up (1986–1988 to 1996–1998), The Pittsburgh Epidemiology of Diabetes Complications Study

 

View this table:
[in this window]
[in a new window]

  		TABLE 2. Duration-adjusted Cox proportional hazards ratios for predicting the incidence of complications during 10 years of follow-up (1986–1988 to 1996–1998), The Pittsburgh Epidemiology of Diabetes Complications Study

 
Figure 1 presents the TSSA results for confirmed distal symmetric polyneuropathy. As shown, 370 individuals were free of this complication at baseline; 114 (30.8 percent) of them developed it during the follow-up period. Starting with the group of 370, the tree first classified subjects by splitting on estimated glucose disposal rate, then age at diabetes onset, and then duration of diabetes (for those whose age at diabetes onset was ≤8.4 years), or white blood cell count for individuals whose age at diabetes onset was >8.4 years. The lowest incidence of confirmed distal symmetric polyneuropathy was observed in the second group; that is, among patients whose estimated glucose disposal rate was more than 6 mg/kg per minute, whose age at diabetes onset was ≤8.4 years, and whose duration of diabetes was less than approximately 24 years. In this lowest-risk group, a nominally significantly greater risk of confirmed distal symmetric polyneuropathy was observed for the eNOS GG genotype, with a diabetes duration–adjusted hazard ratio of 4.86 (95 percent confidence interval: 1.04, 22.72; p < 0.05) (table 3).


Figure 1
View larger version (11K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		FIGURE 1. Tree-structured survival analysis classification for confirmed distal symmetric polyneuropathy (CDSP), The Pittsburgh Epidemiology of Diabetes Complications Study, 10-year follow-up (1986–1988 to 1996–1998). Age at onset (years); duration (years); eGDR, estimated glucose disposal rate (mg/kg per minute); WBC, white blood cell count x 103/mm2.

 

View this table:
[in this window]
[in a new window]

  		TABLE 3. Duration-adjusted Cox proportional hazards ratios for predicting the incidence of complications in the lowest-risk complication groups, as identified by tree-structured survival analysis, The Pittsburgh Epidemiology of Diabetes Complications Study (10 years of follow-up: 1986–1988 to 1996–1998)

 
A total of 392 subjects were free of overt nephropathy at baseline (figure 2), and 49 (12.5 percent) of them developed this complication during the follow-up period. Once again, the tree first classified subjects by splitting on estimated glucose disposal rate, then age at diabetes onset, and, for those whose age at diabetes onset was greater than 7 years, white blood cell count. The first group, that is, subjects whose estimated glucose disposal rate was >6.58, had the lowest incidence of overt nephropathy (8.8 percent), where there was some indication that the D allele of the ACE polymorphism was associated with increased risk of overt nephropathy incidence (table 3; diabetes duration–adjusted hazard ratio = 2.11, 95 percent confidence interval: 1.00, 4.48; p = 0.05). In addition, the protective effect of the LIPC CC genotype (table 3; diabetes duration–adjusted hazard ratio = 0.39, 95 percent confidence interval: 0.18, 0.88; p < 0.05) remained.


Figure 2
View larger version (9K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		FIGURE 2. Tree-structured survival analysis classification for overt nephropathy (ON), The Pittsburgh Epidemiology of Diabetes Complications Study, 10-year follow-up (1986–1988 to 1996–1998). Age at onset (years); eGDR, estimated glucose disposal rate (mg/kg per minute); WBC, white blood cell count x 103/mm2.

 
Ninety-nine of 539 subjects free of coronary artery disease at the baseline examination (figure 3) developed this complication during the 10-year follow-up. This time, diabetes duration emerged as the most consequential predictor, followed by white blood cell count and either serum creatinine (among those whose white blood cell count was <8 x 103/mm2) or HDL cholesterol (in individuals with a high white blood cell count). Patients in the first group, that is, whose diabetes duration was ≤21.19 years, exhibited the lowest incidence of coronary artery disease (6.3 percent); thus, we chose this group to look for significant genetic associations. The CC genotype of the MTHFR C677T gene polymorphism was associated with an approximately threefold risk of coronary artery disease (table 3; diabetes duration–adjusted hazard ratio = 2.95, 95 percent confidence interval: 1.02, 8.50; p < 0.05).


Figure 3
View larger version (11K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		FIGURE 3. Tree-structured survival analysis classification for coronary artery disease (CAD), The Pittsburgh Epidemiology of Diabetes Complications Study, 10-year follow-up (1986–1988 to 1996–1998). Duration (years); creatinine (serum) (mg/dl); WBC, white blood cell count x 103/mm2; HDL, high density lipoprotein cholesterol (mmol/liter).

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
References
 
TSSA is an exploratory statistical method of categorizing individuals into meaningful prognostic subsets. Being nonparametric, this technique requires fewer modeling assumptions. Moreover, because it is designed to categorize persons into risk groups based on survival, it allows for further comparisons within these selected strata. However, tree methods are not without limitations. An important drawback is the inability to assess a covariate's importance because the method relies on post hoc tests; highly correlated covariates may also affect factor selection in recursive partitioning (12Go).

In this study, we used TSSA to identify individuals at seemingly low risk of developing diabetes-related complications and then looked for significant genetic associations that might help explain case development within these lowest-risk subgroups. Indeed, genetic risk factors that were generally not apparent in the total study population emerged within the lowest-risk subgroups.

Interestingly, with the exception of diabetes duration, risk factors chosen for confirmed distal symmetric polyneuropathy (estimated glucose disposal rate, age at diabetes onset, white blood cell count) also seemed to predict incidence of overt nephropathy, although slightly different cutpoints were used each time. This finding is consistent with our previous hypothesis that insulin resistance underlies overt nephropathy susceptibility (9Go). However, although insulin sensitivity alone was adequate to identify the lowest incidence rate of overt nephropathy, for confirmed distal symmetric polyneuropathy, younger age at diabetes onset and shorter diabetes duration were also required. Duration of diabetes, white blood cell count, serum creatinine, and HDL cholesterol concentration were selected as the best predictors of coronary artery disease incidence, and the lowest incidence rate was observed in the subgroup with a shorter duration of diabetes.

The prognostic value of the factors selected by TSSAs has been previously demonstrated in other populations as well. Cardiovascular risk factors (35Go), insulin resistance (36Go), and inflammatory markers (36Go, 37Go) have all been implicated in the development of diabetic neuropathy. Reduced insulin sensitivity has been reported among individuals with diabetes and microalbuminuria (38Go, 39Go), whereas elevated white blood cell count has been shown to predict the development of renal disease in diabetics (40Go, 41Go). Decreased HDL cholesterol concentration (42Go, 43Go) and increased levels of inflammatory markers (37Go, 42Go) are recognized predictors of cardiovascular disease incidence. Furthermore, a variety of studies have shown that renal dysfunction increases the risk of cardiovascular disease (43Go–45Go).

Although the 10-year incidence of confirmed distal symmetric polyneuropathy was approximately 31 percent in the study cohort, the rate was only 8.9 percent in the lowest-risk group (group 2), as assessed by TSSA. In this subgroup, the GG genotype of the eNOS Glu 298 Asp polymorphism was significantly associated with an almost fivefold risk of confirmed distal symmetric polyneuropathy.

Nitric oxide synthases produce nitric oxide, known to play an important role in regulation of the cardiovascular, central, and peripheral nervous systems (46Go). The G to T polymorphism at position 894 of the eNOS gene is the only polymorphism identified to date that changes the eNOS protein sequence, suggesting that genetic variation at this site may alter eNOS activity or regulation (47Go). Synthesis of nitric oxide is thought to be deficient in diabetes (48Go, 49Go), and chronic treatment of nondiabetic rats with a nitric oxide synthase inhibitor has been associated with nerve conduction velocity deficits similar to those observed in diabetes (50Go, 51Go). In experimental studies, nitric oxide has also been associated with neuropathy (52Go, 53Go).

The insertion/deletion polymorphism in intron 16 of the ACE gene determines most of the interindividual variation in ACE levels (54Go). Despite some disagreement (55Go–57Go), this polymorphism has been associated with diabetic nephropathy (9Go, 58Go–62Go) as well as insulin resistance (63Go–65Go). An association similar to the one observed in this report for the D allele has been previously described by our group; we used an alternative approach to compare low- and high-risk groups (i.e., comparing those who develop overt nephropathy early (short duration and before other complications) with those developing this complication late (long duration and after other complications)) (9Go). Furthermore, a recently published meta-analysis suggests that treatment with ACE inhibitors may significantly reduce albuminuria (66Go), providing further support for a role of the ACE gene in renal disease.

The human LIPC polymorphism that we examined is one of four identified polymorphisms of the human LIPC gene (67Go). Allelic variation in the genes encoding LIPC accounts for 25 percent of total interindividual variation in plasma HDL cholesterol levels (68Go). In a report from the Bogalusa Heart Study, the -514T variant of the hepatic lipase gene was associated with higher levels of HDL cholesterol longitudinally since childhood (69Go). The same variant was also associated with significant variations in the lipoprotein profile of male and female participants of the Framingham Offspring Study, where increases were noted in large HDL subfractions among carriers of the -514 allele (32Go). Furthermore, LIPC appears to relate to markers of cardiovascular disease in type 1 diabetes (70Go). In the present analyses, a protective effect of the CC genotype of the LIPC C(-514)T polymorphism was observed for those at the lowest risk of overt nephropathy. We (9Go), among other groups (71Go–73Go), have shown that serum lipid levels are associated with overt nephropathy incidence.

With regard to coronary artery disease, the incidence rate in the lowest-risk group, as derived from TSSA, was 6.3 percent compared with an overall rate of 18.4 percent. An increased risk associated with the CC genotype in the MTHFR C677T gene polymorphism was noted. Recently, a number of studies (74Go–77Go) have supported a role of the C677T variant in the pathophysiology of cardiovascular disease. Such an association seems likely because of its influence on homocysteine levels (78Go), although, in this cohort, homocysteine levels were not related to either the MTHFR genotype or coronary artery disease incidence (data not shown).

In conclusion, genetic risk factors may be better identified in subgroups characterized by the absence of major traditional risk factors. It is important to note that, with the exception of the LIPC CC genotype, none of the other polymorphisms were associated with complication outcome in the total study population; associations with gene polymorphisms emerged in the lowest-risk subgroups only. This approach provides the potential for further insight into genetic variations and their role in the development of complications. It may be helpful in formulating prevention strategies by focusing attention on the newly defined high-risk population subgroups as well as addressing standard risk factors. However, the present genetic associations were derived essentially from hypothesis-generating analyses and need to be evaluated and replicated in other populations before acceptance.


APPENDIX TABLE 1. Other candidate genes for the study of type 1 diabetes complications in The Pittsburgh Epidemiology of Diabetes Complications Study

Gene
Rationale
Apolipoprotein E: Apo E2, Apo E3, Apo E4 Key role in triglycerides metabolism, transcription regulated by insulin (Talmud PJ, Humphries SE. Apolipoprotein C-III gene variation and dyslipidaemia. Curr Opin Lipidol 1997;8:154–8; Chen M, Breslow JL, Li W, et al. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J Lipid Res 1994;35:1918–24).
Lipoprotein lipase: LPL Hind 3 Major determinant of high density lipoprotein cholesterol and triglyceride levels (Fisher RM, Humphries SE, Talmud PJ. Common variation in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis. Atherosclerosis 1997;135:145–59; Wang XL, McCredie RM, Wilcken DE. Common DNA polymorphisms at the lipoprotein lipase gene. Association with severity of coronary artery disease and diabetes. Circulation 1996;93:1339–45).
Prohormone convertase 1: PC1 Lys121Gln (K121Q) L cells express PC1/3 (Scopsi L, Gullo M, Rilke F, et al. Proprotein convertases (PC1/PC3 and PC2) in normal and neoplastic human tissues: their use as markers of neuroendocrine differentiation. J Clin Endocrinol Metab 1995;80:294–301; Tanaka S, Kurabuchi S, Mochida H, et al. Immunocytochemical localization of prohormone convertases PC1/PC3 and PC2 in rat pancreatic islets. Arch Histol Cytol 1996;59:261–71), and it could be expected that PC1/3 mainly cleave the C-terminal part of Pg, forming GLP-1 and GLP-2.
Cell adhesion marker P-selectin: P-selectin Thr741 Thr, P-selectin Thr715Pro (T715P) Adherence of circulating mononuclear cells to the activated endothelium is an early event in the pathogenesis of atherosclerosis, and variation in cell adhesion molecules is associated with atherosclerosis (Frenette PS, Wagner DD. Adhesion molecules—Part II: blood vessels and blood cells. N Engl J Med 1996;335:43–5; Wenzel K, Ernst M, Rohde K, et al. DNA polymorphisms in adhesion molecule genes—a new risk factor for early atherosclerosis. Hum Genet 1996;97:15–20).
Peroxisome proliferator activated receptor gamma 2: PPARG Pro12Ala (P12A) PPAR gamma2 is a nuclear factor known to be an important regulator of lipid and glucose metabolism and fatty acid transport (Way JM, Harrington WW, Brown KK, et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 2001;142:1269–77) and has been associated with risk of diabetic nephropathy (Caramori ML, Canani LH, Costa LA, et al. The human peroxisome proliferator-activated receptor {gamma}2 (PPAR{gamma}2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes 2003;52:3010–13).
Receptor for advanced glycation end-products: RAGE Gly82Ser (G82S) Promotes vascular permeability and expression of vascular adhesion molecules (Chappey O, Dosquet C, Wautier MP, et al. Advanced glycation end products, oxidant stress and vascular lesions. Eur J Clin Invest 1997;27:97–108; Yan SD, Stern D, Schmidt AM. What's the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucose. Eur J Clin Invest 1997;27:179–81; Miura J, Uchigata Y, Yamamoto Y, et al. AGE down-regulation of monocyte RAGE expression and its association with diabetic complications in type 1 diabetes. J Diabetes Complications 2004;18:53–9; Wendt T, Tanji N, Guo J, et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 2003;14:1383–95).
Aldose reductase: ALR2 C(-106)T
 Up-regulated in diabetic nephropathy and allelic variation associated with nephropathy in diabetes (Shah VO, Dorin RI, Sun Y, et al. Aldose reductase gene expression is increased in diabetic nephropathy. J Clin Endocrinol Metab 1997;82:2294–8; Heesom AE, Hibberd ML, Millward A, et al. Polymorphism in the 5'-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes. Diabetes 1997;46:287–91; Wang Y, Ng MC, Lee SC, et al. Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes. Diabetes Care 2003;26:2410–15).


   ACKNOWLEDGMENTS
 
This work was supported by National Institutes of Health grant DK34818.

The authors thank the Pittsburgh Epidemiology of Diabetes Complications Study staff.

Conflict of interest: none declared.


   References
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 References
 

  1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977–86.[Abstract/Free Full Text]
  2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837–53.[CrossRef][Web of Science][Medline]
  3. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. JAMA 2003;290:2159–67.[Abstract/Free Full Text]
  4. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000;342:381–9.[Abstract/Free Full Text]
  5. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997;46:1829–39.[Abstract]
  6. Seaquist ER, Goetz FC, Rich S, et al. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989;320:1161–5.[Abstract]
  7. Pettitt DJ, Saad MF, Bennett PH, et al. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1990;33:438–43.[CrossRef][Web of Science][Medline]
  8. Rich SS, Freedman BI, Bowden DW. Genetic epidemiology of diabetic complications. Diabet Rev 1997;5:165–73.
  9. Orchard TJ, Chang YF, Ferrell RE, et al. Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int 2002;62:963–70.[CrossRef][Web of Science][Medline]
  10. Cox DR. Regression models and life tables (with discussion). J R Stat Soc (B) 1972;34;187–220.
  11. Breiman L, Friedman JA, Olshen R, et al. Classification and regression tree. New York, NY: Wadsworth, 1984.
  12. Segal MR. Features of tree-structured survival analysis. Epidemiology 1997;8:344–6.[Web of Science][Medline]
  13. Segal MR. Regression trees for censored data. Biometrics 1988;44:35–47.[CrossRef][Web of Science]
  14. Orchard TJ, Dorman JS, Maser RE, et al. Prevalence of complications of IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 1990;39:1116–24.[Abstract]
  15. Orchard TJ, Dorman JS, Maser RE, et al. Factors associated with avoidance of severe complications after 25 yr of IDDM. Pittsburgh Epidemiology of Diabetes Complications Study I. Diabetes Care 1990;13:741–7.[Abstract]
  16. Wagener DK, Sacks JM, LaPorte RE, et al. The Pittsburgh study of insulin-dependent diabetes mellitus. Risk for diabetes among relatives of IDDM. Diabetes 1982;31:136–44.[Abstract]
  17. Feldman EL, Stevens MJ, Thomas PK, et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994;17:1281–9.[Abstract]
  18. Maser RE, Nielsen VK, Bass EB, et al. Measuring diabetic neuropathy: assessment and comparison of clinical examination and quantitative sensory testing. Diabetes Care 1989;12:270–5.[Abstract]
  19. Arezzo JC. Quantitative sensory testing of vibration threshold vibratron. II. Rationale and methods. Clifton, NJ: Physitemp Instruments, Inc, 1993.
  20. Borhani NO, Kass EH, Langford HG, et al. The hypertension detection and follow-up program. Prev Med 1976;5:207–15.[CrossRef][Web of Science][Medline]
  21. Warnick GR, Albers JJ. Heparin—Mn2+ quantitation of high-density-lipoprotein cholesterol: an ultrafiltration procedure for lipemic samples. Clin Chem 1978;24:900–4.[Abstract/Free Full Text]
  22. Lipid Research Clinics Program. Lipid and lipoprotein analysis. In: Manual of laboratory operations. US Department of Health, Education and Welfare. Washington, DC: US Government Printing Office, 1975. (Publication no. 75-628).
  23. Allain CC, Poon LS, Chan CSG, et al. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470–5.[Abstract]
  24. Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973;19:476–82.[Abstract]
  25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.[Abstract]
  26. Williams KV, Erbey JR, Becker DJ, et al. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 2000;49:626–32.[Abstract]
  27. Miller SA, Dykes DP, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.[Free Full Text]
  28. Tiret L, Rigat B, Visvikis S, et al. Evidence from combined linkage and segregation analysis that a variant of the ACE gene controls plasma ACE levels. Am J Hum Genet 1992;51:197–205.[Web of Science][Medline]
  29. Frosst P, Blom HJ, Milos R, et al. A candidate risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111–13.[CrossRef][Web of Science][Medline]
  30. Nakayama M, Yasue H, Yoshimura M, et al. T-786C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999;99:2864–70.[Abstract/Free Full Text]
  31. Hibi K, Ishigami T, Tamura K, et al. Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension 1998;32:521–6.[Abstract/Free Full Text]
  32. Couture P, Otvos JD, Cupples LA, et al. Association of the C-514T polymorphism in the hepatic lipase gene with variations in lipoprotein subclass profiles: The Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2000;20:815–22.[Abstract/Free Full Text]
  33. Forrest KY, Maser RE, Pambianco G, et al. Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes 1997;46:665–70.[Abstract]
  34. Orchard TJ, Olson JC, Erbey JR, et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2003;26:1374–9.[Abstract/Free Full Text]
  35. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005;352:341–50.[Abstract/Free Full Text]
  36. González-Clemente JM, Mauricio D, Richart C, et al. Diabetic neuropathy is associated with activation of the TNF-alpha system in subjects with type 1 diabetes mellitus. Clin Endocrinol (Oxf) 2005;63:525–9.[CrossRef][Medline]
  37. Schram MT, Chaturvedi N, Schalkwijk CG, et al. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes—the EURODIAB Prospective Complications Study. Diabetologia 2005;48:370–8.[CrossRef][Web of Science][Medline]
  38. Yip J, Mattock MB, Morocutti A, et al. Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet 1993;342:883–7.[CrossRef][Web of Science][Medline]
  39. Ekstrand AV, Groop PH, Grönhagen-Riska C. Insulin resistance precedes microalbuminuria in patients with insulin-dependent diabetes mellitus. Nephrol Dial Transplant 1998;13:3079–83.[Abstract/Free Full Text]
  40. Chung FM, Tsai JCR, Chang DM, et al. Peripheral total and differential leukocyte count in diabetic nephropathy. Diabetes Care 2005;28:1710–17.[Abstract/Free Full Text]
  41. Cavalot F, Massucco P, Perna P, et al. White blood cell count is positively correlated with albumin excretion rate in subjects with type 2 diabetes. Diabetes Care 2002;25:2354–5.[Free Full Text]
  42. Saito I, Folsom AR, Brancati FL, et al. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med 2000;133:81–91.[Abstract/Free Full Text]
  43. Soedamah-Muthu SS, Chaturvedi N, Toeller M, et al. Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. Diabetes Care 2004;27:530–7.[Abstract/Free Full Text]
  44. Krolewski AS, Kosinski EJ, Warram JH, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1997;59:750–5.
  45. Torffvit O, Lovestam-Adrian M, Agardh E, et al. Nephropathy, but not retinopathy, is associated with the development of heart disease in type 1 diabetes: a 12-year observation study of 462 patients. Diabet Med 2005;22:723–9.[CrossRef][Web of Science][Medline]
  46. Moncada S, Higgs EA. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J 1995;9:1319–30.[Abstract]
  47. Guzik TJ, Black E, West NEJ, et al. Relationship between the G894T polymorphism (Glu 298 Asp variant) in endothelial nitric oxide synthase and nitric oxide-mediated endothelial function in human atherosclerosis. Am J Med Genet 2001;100:130–7.[CrossRef][Web of Science][Medline]
  48. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997;48:489–509.[CrossRef][Web of Science][Medline]
  49. Harrison DG. Cellular and molecular mechanisms of endothelial dysfunction. J Clin Invest 1998;100:2153–7.[CrossRef][Web of Science]
  50. Cameron NE, Cotter MA, Dines KC, et al. Pharmacological manipulation of vascular endothelium in non-diabetic and streptozotocin-diabetic rats: effects on nerve conduction, hypoxic resistance and endoneurial capillarization. Diabetologia 1993;36:516–22.[Web of Science][Medline]
  51. Stevens MJ, Dananberg J, Feldman EL, et al. The linked roles of nitric oxide, aldose reductase and (Na+, K+)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest 1994;94:853–9.[Web of Science][Medline]
  52. Cotter MA, Ekberg K, Wahren J, et al. Effects of proinsulin C-peptide in experimental diabetic neuropathy. Vascular actions and modulation by nitric oxide synthase inhibition. Diabetes 2003;52:1812–17.[Abstract/Free Full Text]
  53. Maxfield EK, Cameron NE, Cotter MA. Effects of diabetes on reactivity of sciatic vasa nervorum in rats. J Diabetes Complications 1997;11:47–55.[CrossRef][Web of Science][Medline]
  54. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion deletion polymorphism in angiotensin I conversion enzyme accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343–6.[Web of Science][Medline]
  55. Araz M, Yilmaz N, Gungor K, et al. Angiotensin-converting enzyme gene polymorphism and microvascular complications in Turkish type 2 diabetic patients. Diabetes Res Clin Pract 2001;54:95–104.[CrossRef][Web of Science][Medline]
  56. van Ittersum FJ, de Man AM, Thijssen S, et al. Genetic polymorphisms of the renin-angiotensin system and complications of insulin-dependent diabetes mellitus. Nephrol Dial Transplant 2000;15:1000–7.[Abstract/Free Full Text]
  57. De Cosmo S, Margaglione M, Tassi V, et al. ACE, PAI-1, decorin and Werner helicase genes are not associated with the development of renal disease in European patients with type 1 diabetes. Diabetes Metab Res Rev 1999;15:247–53.[CrossRef][Web of Science][Medline]
  58. Kuramoto N, Iizuka T, Ito H, et al. Effect of ACE gene on diabetic nephropathy in NIDDM patients with insulin resistance. Am J Kidney Dis 1999;33:276–81.[Web of Science][Medline]
  59. Ha SK, Yong Lee S, Su Park H, et al. ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric non-insulin-dependent diabetes mellitus. Nephrol Dial Transplant 2000;15:1617–23.[Abstract/Free Full Text]
  60. Rudberg S, Rasmussen LM, Bangstad HJ, et al. Influence of insertion/deletion polymorphism in the ACE-I gene on the progression of diabetic glomerulopathy in type 1 diabetic patients with microalbuminuria. Diabetes Care 2000;23:544–8.[Abstract]
  61. Azar ST, Zalloua PA, Medlej R, et al. The DD genotype of the ACE gene polymorphism is associated with diabetic nephropathy in the type-1 diabetics. Endocr Res 2001;27:99–108.[CrossRef][Web of Science][Medline]
  62. Hadjadj S, Belloum R, Bouhanick B, et al. Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: a prospective study. J Am Soc Nephrol 2001;12:541–9.[Abstract/Free Full Text]
  63. Panahloo A, Andres C, Mohamed-Ali V, et al. The insertion allele of the ACE gene I/D polymorphism. A candidate gene for insulin resistance? Circulation 1995;92:3390–3.[Abstract/Free Full Text]
  64. Chiu KC, McCarthy JE. The insertion allele at the angiotensin I-converting enzyme gene locus is associated with insulin resistance. Metabolism 1997;46:395–9.[CrossRef][Web of Science][Medline]
  65. Ryan AS, Nicklas BJ, Berman DM, et al. The insertion/deletion polymorphism of the ACE gene is related to insulin sensitivity in overweight women. Diabetes Care 2001;24:1646–52.[Abstract/Free Full Text]
  66. Hamilton RA, Kane MP, Demers J. Angiotensin-converting enzyme inhibitors and type 2 diabetic nephropathy: a meta-analysis. Pharmacotherapy 2003;23:909–15.[CrossRef][Web of Science][Medline]
  67. Guerra R, Wang J, Grundy SM, et al. A hepatic lipase (LIPC) allele associated with plasma concentration of high density lipoprotein cholesterol. Proc Natl Acad Sci U S A 1997;94:4532–7.[Abstract/Free Full Text]
  68. Cohen JC, Wang Z, Grundy SM, et al. Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels. J Clin Invest 1994;94:2377–84.[Web of Science][Medline]
  69. Chen W, Srinivasan SR, Boerwinkle E, et al. Hepatic lipase promoter C-514T polymorphism influences serial changes in HDL cholesterol levels since childhood: the Bogalusa Heart Study. Atherosclerosis 2003;169:175–82.[CrossRef][Web of Science][Medline]
  70. Hokanson JE, Cheng S, Snell-Bergeon JK, et al. A common promoter polymorphism in the hepatic lipase gene (LIPC–480C>T) is associated with an increase in coronary calcification in type 1 diabetes. Diabetes 2002;51:1208–13.[Abstract/Free Full Text]
  71. Gall MA, Hougaard P, Borch-Johnsen K, et al. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 1997;314:783–8.[Abstract/Free Full Text]
  72. Ravid M, Brosh D, Ravid-Safran D, et al. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998;158:998–1004.[Abstract/Free Full Text]
  73. Esmatjes E, De Alvaro F, ‘Estudio Diamante’ Investigators. Incidence of diabetic nephropathy in type 1 diabetic patients in Spain: ‘Estudio Diamante’. Diabetes Res Clin Pract 2002;57:35–43.[CrossRef][Web of Science][Medline]
  74. Kluijtmans LA, Kastelein JJ, Lindemans J, et al. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1997;96:2573–7.[Abstract/Free Full Text]
  75. Meleady R, Ueland PM, Blom H, et al. Thermolabile methylenetetrahydrofolate reductase, homocysteine, and cardiovascular disease risk: the European Concerted Action Project. Am J Clin Nutr 2003;77:63–70.[Abstract/Free Full Text]
  76. Andreassi MG, Botto N, Cocci F, et al. Methylenetetrahydrofolate reductase gene C677T polymorphism, homocysteine, vitamin B12, and DNA damage in coronary artery disease. Hum Genet 2003;112:171–7.[Web of Science][Medline]
  77. Girelli D, Martinelli N, Pizzolo F, et al. The interaction between MTHFR 677 C–>T genotype and folate status is a determinant of coronary atherosclerosis risk. J Nutr 2003;133:1281–5.[Abstract/Free Full Text]
  78. Brattstrom L, Wilcken DE, Ohrvik J, et al. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998;98:2520–6.[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arch Intern MedHome page
E. Zintzaras, G. Raman, G. Kitsios, and J. Lau
Angiotensin-Converting Enzyme Insertion/Deletion Gene Polymorphic Variant as a Marker of Coronary Artery Disease: A Meta-analysis
Arch Intern Med, May 26, 2008; 168(10): 1077 - 1089.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. Kretowski, K. McFann, J. E. Hokanson, D. Maahs, G. Kinney, J. K. Snell-Bergeon, R. P. Wadwa, R. H. Eckel, L. Ogden, S. Garg, et al.
Polymorphisms of the Renin-Angiotensin System Genes Predict Progression of Subclinical Coronary Atherosclerosis
Diabetes, March 1, 2007; 56(3): 863 - 871.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
164/9/862    most recent
kwj287v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Costacou, T.
Right arrow Articles by Orchard, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Costacou, T.
Right arrow Articles by Orchard, T. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?